ArticleCureus2024
Hepatitis Secondary to an Over-the-Counter Appetite Stimulant: A Case Report.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We present the case of a previously healthy 11-year-old boy who developed hepatitis in the setting of regular intake of Apetamin. Apetamin is an appetite stimulant not approved by the United States Food and Drug Administration that contains cyproheptadine, lysine, and multiple B vitamins. It is illegally imported into the United States and can be purchased online. The patient was referred to the gastrointestinal clinic for evaluation of hepatitis based on screening laboratory testing collected during a routine healthcare visit. Laboratory workup revealed elevated transaminases six months after beginning Apetamin and positive anti-smooth muscle antibody. Liver enzymes improved following the discontinuation of Apetamin. The case highlights the potential of dietary supplements to cause hepatic injury and the importance of a thorough history of complementary alternative medication usage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.